Literature DB >> 11292878

Increasing prevalence of antimicrobial resistance in intensive care units.

S K Fridkin1.   

Abstract

The unique nature of the intensive care unit (ICU) environment makes this part of the hospital a focus for the emergence and spread of many antimicrobial-resistant pathogens. There are ample opportunities for the cross-transmission of resistant bacteria from patient to patient, and patients are commonly exposed to broad-spectrum antimicrobial agents. Rates of resistance have increased for most pathogens associated with hospital-acquired infections among ICU patients, and rates are almost universally higher among ICU patients than non-ICU patients. Likewise, ICU patients hospitalized longer (i.e., >7 days) are two- to three-fold more likely to be infected with a pathogen possessing an antimicrobial-resistant phenotype of concern. However, there are many opportunities to prevent the emergence and spread of these resistant pathogens through improved use of established infection control measures (patient isolation, handwashing, glove use, and appropriate gown use) and implementation of a systematic review of antimicrobial use. (Crit Care Med 2001; 29[Suppl.]: N64-N68)

Entities:  

Mesh:

Year:  2001        PMID: 11292878     DOI: 10.1097/00003246-200104001-00002

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  43 in total

1.  Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals.

Authors:  Carl T Bergstrom; Monique Lo; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-12       Impact factor: 11.205

2.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

3.  The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  N Shime; T Kosaka; N Fujita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-14       Impact factor: 3.267

4.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

5.  Current problems in the diagnosis and treatment of hospital-acquired methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Masahiro Sakaguchi; Nobuaki Shime; Naohisa Fujita; Sakiko Fujiki; Satoru Hashimoto
Journal:  J Anesth       Date:  2008-05-25       Impact factor: 2.078

6.  Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.

Authors:  Thomas P Lodise; Mark Gotfried; Steven Barriere; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

Review 7.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

8.  Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004.

Authors:  E Meyer; F Schwab; P Gastmeier; H Rueden; F D Daschner
Journal:  Infection       Date:  2006-12       Impact factor: 3.553

9.  Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999.

Authors:  Susan S Huang; Brian J Labus; Michael C Samuel; Dairian T Wan; Arthur L Reingold
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

10.  Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock.

Authors:  Suresh Ramasubban; Ayanava Majumdar; Purnendu Sekhar Das
Journal:  Indian J Crit Care Med       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.